- Home
- AC vs STOK Comparison
AC vs STOK Comparison
Compare AC & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AC
- STOK
- Stock Information
- Founded
- AC 1976
- STOK 2014
- Country
- AC United States
- STOK United States
- Employees
- AC N/A
- STOK N/A
- Industry
- AC Investment Bankers/Brokers/Service
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- AC Finance
- STOK Health Care
- Exchange
- AC Nasdaq
- STOK Nasdaq
- Market Cap
- AC 774.7M
- STOK 721.4M
- IPO Year
- AC N/A
- STOK 2019
- Fundamental
- Price
- AC $36.33
- STOK $11.24
- Analyst Decision
- AC
- STOK Strong Buy
- Analyst Count
- AC 0
- STOK 8
- Target Price
- AC N/A
- STOK $21.83
- AVG Volume (30 Days)
- AC 4.6K
- STOK 743.6K
- Earning Date
- AC 11-08-2024
- STOK 11-05-2024
- Dividend Yield
- AC 0.57%
- STOK N/A
- EPS Growth
- AC 65.12
- STOK N/A
- EPS
- AC 2.62
- STOK N/A
- Revenue
- AC $13,657,000.00
- STOK $16,742,999.00
- Revenue This Year
- AC N/A
- STOK $103.66
- Revenue Next Year
- AC N/A
- STOK N/A
- P/E Ratio
- AC $13.47
- STOK N/A
- Revenue Growth
- AC N/A
- STOK 81.08
- 52 Week Low
- AC $28.58
- STOK $4.09
- 52 Week High
- AC $43.85
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- AC 51.57
- STOK 40.47
- Support Level
- AC $33.60
- STOK $10.61
- Resistance Level
- AC $35.88
- STOK $11.84
- Average True Range (ATR)
- AC 1.01
- STOK 0.82
- MACD
- AC -0.05
- STOK -0.12
- Stochastic Oscillator
- AC 56.08
- STOK 16.69
About AC Associated Capital Group Inc.
Associated Capital Group Inc is a diversified global financial services company. It operates in the business of alternative investment management, institutional research services, and cash and other assets through subsidiaries. The activities of its subsidiaries comprise publishing daily research notes and full reports using private market value with a catalyst methodology and also products and customized solutions utilizing private market value with catalyst method of investing.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.